Kymera Therapeutics reported second quarter 2026 financial results, recognizing $65.0 million in collaboration revenue driven by a $45 million option exercise fee from Gilead Sciences for KT-200 and a $20 million milestone payment from Sanofi for KT-485. The company posted a net loss of $61.2 million against R&D expenses of $119.5 million, while maintaining $1.5 billion in cash as of June 30, 2026. Clinically, enrollment in the Phase 2b BROADEN2 trial for KT-621 (STAT6) in atopic dermatitis completed nearly six months ahead of schedule, accelerating data readout to year-end 2026 and enabling a planned Phase 3 initiation by mid-2027. The company also appointed Felix J. Baker as Chairman and Terence Rooney as Chief Medical Officer. Kymera Therapeutics is a clinical-stage biotechnology company pioneering targeted protein degradation to develop oral small molecule therapies for immunological diseases.

Kymera Therapeutics, Inc. announced the retirement of Chief Medical Officer Jared Gollob, M.D., effective July 27, 2026, and the appointment of Terence Rooney, M.D., as the new Chief Medical Officer. Dr. Rooney, formerly a senior vice president at Johnson & Johnson, immunology leader, and experience with several successful marketing applications, is succeeding Dr. Gollob thanks to his extensive experience in immunology drug development. Dr. Gollob will remain as an advisor to the company as an advisor until December 31, 2026. Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing oral small molecule degrader medicines for immunological diseases.

On June 25, 2026, Kymera Therapeutics announced the completion of enrollment for the global BROADEN2 Phase 2b trial of KT-621, an oral STAT6 degrader for moderate to severe atopic dermatitis. Enrollment finished ahead of schedule, accelerating the expected topline data readout to year-end 2026, approximately six months earlier than the previous mid-2027 estimate. The company expects to initiate Phase 3 trials by mid-2027, pending regulatory discussions. Kymera Therapeutics is a biopharmaceutical company that develops targeted protein degradation therapies.

Jeremy Chadwick, the Chief Operating Officer (COO) of Kymera Therapeutics, Inc., has announced his intention to retirement and submitted his resignation as COO effective June 5, 2026. He will remain with the company as an advisor until November 2026. He resigned for personal reasons and not due to any disagreement with the company's practices or policies.